Information Provided By:
Fly News Breaks for September 7, 2017
ENDP, COLL
Sep 7, 2017 | 05:55 EDT
Jefferies analyst David Steinberg says shares of Collegium Pharmaceutical (COLL) have been weak despite the acceleration of Xtampza prescription trends since June. With the company likely on track to exceed expectations, the valuation at current share levels "looks very attractive," Steinberg tells investors in a research note. He also believes the benefit from Endo's (ENDP) Opana market withdrawal may start kicking in soon. The analyst keeps a Buy rating on Collegium with a $15 price target.
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.